The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

Elotuzumab is a humanized therapeutic monoclonal antibody directed to the surface glycoprotein SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) tumor cells. Improved clinical outcomes have been observed following treatment of MM patients with elotuzumab in combination w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Pazina, Tatiana, James, Ashley M., MacFarlane, Alexander W., Bezman, Natalie A., Henning, Karla A., Bee, Christine, Graziano, Robert F., Robbins, Michael D., Cohen, Adam D., Campbell, Kerry S.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2017
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599094/
https://ncbi.nlm.nih.gov/pubmed/28932638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1339853
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items